Chitosan Functionalized MnO Nanoparticles Counteracts Ulcerative Colitis in Mice Through Modulation of Cellular Redox State

Overview

Journal Commun Biol

Specialty Biology

Date 2023 Jun 16

PMID 37328528

Authors

Susmita Mondal

Monojit Das

Ria Ghosh

Manali Singh

Aniruddha Adhikari

Soumendra Darbar

Anjan Kumar Das

Siddhartha Sankar Bhattacharya

Debasish Pal

Debasish Bhattacharyya

Ahmed S A Ahmed

Asim Kumar Mallick

Munirah M Al-Rooqi

Ziad Moussa

Saleh A Ahmed

Samir Kumar Pal

Affiliations

Soon will be listed here.

Abstract

Recent findings suggest a key role for reactive oxygen species (ROS) in the pathogenesis and progression of ulcerative colitis (UC). Several studies have also highlighted the efficacy of citrate functionalized MnO nanoparticles as redox medicine against a number of ROS-mediated disorders. Here we show that synthesized nanoparticles consisting of chitosan functionalized tri-manganese tetroxide (MnO) can restore redox balance in a mouse model of UC induced by dextran sulfate sodium (DSS). Our in-vitro characterization of the developed nanoparticle confirms critical electronic transitions in the nanoparticle to be important for the redox buffering activity in the animal model. A careful administration of the developed nanoparticle not only reduces inflammatory markers in the animals, but also reduces the mortality rate from the induced disease. This study provides a proof of concept for the use of nanomaterial with synergistic anti-inflammatory and redox buffering capacity to prevent and treat ulcerative colitis.

Citing Articles

Phillygenin ameliorates tight junction proteins reduction, fibrosis, and apoptosis in mice with chronic colitis via TGR5-mediated PERK-eIF2α-Ca pathway.

Xue H, Li P, Guo J, Chen T, Li S, Zhang L J Pharm Anal. 2025; 15(1):101042.

PMID: 39902458 PMC: 11788720. DOI: 10.1016/j.jpha.2024.101042.

Locally Acting Budesonide-Loaded Solid Self-Microemulsifying Drug Delivery Systems (SMEDDS) for Distal Ulcerative Colitis.

Ali H, Hanafy A, Bafail R, Alrbyawi H, Almaghrabi M, Alahmadi Y Int J Nanomedicine. 2024; 19:11819-11846.

PMID: 39558914 PMC: 11570536. DOI: 10.2147/IJN.S484277.

Transforming Medicine with Nanobiotechnology: Nanocarriers and Their Biomedical Applications.

Karnwal A, Sharma V, Kumar G, Jassim A, Dohroo A, Sivanesan I Pharmaceutics. 2024; 16(9).

PMID: 39339152 PMC: 11435024. DOI: 10.3390/pharmaceutics16091114.

A spectroscopy based prototype for the noninvasive detection of diabetes from human saliva using nanohybrids acting as nanozyme.

Roy L, Mondal S, Bhattacharyya N, Ghosh R, Banerjee A, Singh S Sci Rep. 2023; 13(1):17306.

PMID: 37828100 PMC: 10570348. DOI: 10.1038/s41598-023-44011-y.

References

Mosli M, Feagan B, Zou G, Sandborn W, DHaens G, Khanna R . Development and validation of a histological index for UC. Gut. 2015; 66(1):50-58. DOI: 10.1136/gutjnl-2015-310393. View

Mondal S, Adhikari A, Das M, Darbar S, Alharbi A, Ahmed S . Novel one pot synthesis and spectroscopic characterization of a folate-MnO nanohybrid for potential photodynamic therapeutic application. RSC Adv. 2022; 9(52):30216-30225. PMC: 9072110. DOI: 10.1039/c9ra06835j. View

Sandborn W, Feagan B, DHaens G, Wolf D, Jovanovic I, Hanauer S . Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021; 385(14):1280-1291. DOI: 10.1056/NEJMoa2033617. View

Campbell E, Colgan S . Control and dysregulation of redox signalling in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2018; 16(2):106-120. PMC: 7919748. DOI: 10.1038/s41575-018-0079-5. View

Adhikari A, Mondal S, Das M, Biswas P, Pal U, Darbar S . Incorporation of a Biocompatible Nanozyme in Cellular Antioxidant Enzyme Cascade Reverses Huntington's Like Disorder in Preclinical Model. Adv Healthc Mater. 2020; 10(7):e2001736. DOI: 10.1002/adhm.202001736. View

Terdiman J, Gruss C, Heidelbaugh J, Sultan S, Falck-Ytter Y . American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013; 145(6):1459-63. DOI: 10.1053/j.gastro.2013.10.047. View

Adhikari A, Mondal S, Chatterjee T, Das M, Biswas P, Ghosh R . Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice. Commun Biol. 2021; 4(1):1013. PMC: 8390471. DOI: 10.1038/s42003-021-02546-8. View

Torres J, Mehandru S, Colombel J, Peyrin-Biroulet L . Crohn's disease. Lancet. 2016; 389(10080):1741-1755. DOI: 10.1016/S0140-6736(16)31711-1. View

Thapa S, Hadid H, Usman M, Imam W, Hassan A, Schairer J . Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients. Dig Dis Sci. 2015; 61(1):230-7. DOI: 10.1007/s10620-015-3864-9. View

10.

Nel A, Madler L, Velegol D, Xia T, Hoek E, Somasundaran P . Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009; 8(7):543-57. DOI: 10.1038/nmat2442. View

11.

Ways T, Lau W, Khutoryanskiy V . Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers (Basel). 2019; 10(3). PMC: 6414903. DOI: 10.3390/polym10030267. View

12.

Sies H, Jones D . Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020; 21(7):363-383. DOI: 10.1038/s41580-020-0230-3. View

13.

Aspenvall L, Aadland E . [Severe ulcerative colitis]. Tidsskr Nor Laegeforen. 1990; 110(12):1520-2. View

14.

Feuerstein J, Isaacs K, Schneider Y, Siddique S, Falck-Ytter Y, Singh S . AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020; 158(5):1450-1461. PMC: 7175923. DOI: 10.1053/j.gastro.2020.01.006. View

15.

Arai Y, Takanashi H, Kitagawa H, Okayasu I . Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice. Cytokine. 1999; 10(11):890-6. DOI: 10.1006/cyto.1998.0355. View

16.

Foubert P, Kaneda M, Varner J . PI3Kγ Activates Integrin α and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression. Cancer Immunol Res. 2017; 5(11):957-968. PMC: 6422969. DOI: 10.1158/2326-6066.CIR-17-0143. View

17.

Chassaing B, Aitken J, Malleshappa M, Vijay-Kumar M . Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol. 2014; 104:15.25.1-15.25.14. PMC: 3980572. DOI: 10.1002/0471142735.im1525s104. View

18.

Islam M, Murata T, Fujisawa M, Nagasaka R, Ushio H, Bari A . Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice. Br J Pharmacol. 2008; 154(4):812-24. PMC: 2439859. DOI: 10.1038/bjp.2008.137. View

19.

Biasi F, Leonarduzzi G, Oteiza P, Poli G . Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antioxid Redox Signal. 2013; 19(14):1711-47. PMC: 3809610. DOI: 10.1089/ars.2012.4530. View

20.

Rice J, Ihle S . Effects of diet on fecal occult blood testing in healthy dogs. Can J Vet Res. 1994; 58(2):134-7. PMC: 1263679. View